Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood concentrate may boost bone growth for dental implants

NCT ID NCT03495700

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a special blood concentrate (L-PRF) mixed with bone substitute helps grow more bone in the sinus area for people needing dental implants. Twenty-three adults with jawbone loss received either the L-PRF block or a standard bovine bone graft. After six months, the amount of new bone was measured using 3D scans, and implants were followed for up to five years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
L-PRF block (a mix of patient's own blood concentrate and bone substitute) and DBBM (bovine bone graft)
What this could lead to
If L-PRF works better, it could improve bone growth for dental implants, reducing the need for repeat procedures.
What could go wrong
This is a small, early study with only 23 participants, so results may not apply to everyone. The procedure also carries typical surgical risks like infection or graft failure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

23 people

The number who actually took part.

Started

Mar 2018

Finished

Jun 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males and females ≥ 18 years of age. * Ability to understand the nature of the proposed surgical procedure and sign an informed consent form. * ASA I and ASA II. * In need of an implant in the posterior region of the maxilla, * RBH of \<4 mm or RBH \>4 mm but no transcrestal approach possible (due to anatomy). * Healthy oral mucosa and no active periodontal disease. * Edentulous sites consisting of native, non-augmented bone. Exclusion Criteria: * General contraindications for implant placement and/or surgical treatment. * Acute infection or residual lesions in the edentulous sites. * Acute maxillary sinus pathosis. * Ongoing inflammatory and/or autoimmune diseases of the oral cavity. * Patients with poor oral hygiene who are not amenable to improvement. * Immunosuppressants, corticosteroids, or bisphosphonate * History of malignancy, radiotherapy, or chemotherapy for malignancy within the past five years. * Smoker \> 10 cigarettes. * Uncontrolled insulin-dependent diabetes. * Pregnant or lactating women. * Alcohol and drug abuse.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Edentulous; alveolar process, atrophy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Atrophy Mouth, Edentulous

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • UZ Leuven

    Leuven, 3000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.